Literature DB >> 32468464

Nutritional Lipidomics in Alzheimer's Disease.

Efstathia Kalli1.   

Abstract

Lipids constitute almost 60% of the brain's dry weight, and they are thought to be involved in inflammation, neurotransmission and synaptic plasticity. The brain mostly contains sphingolipids, glycerophospholipids and cholesterol which are abundant in myelin and neuronal membranes. The recent rise of the promising area of lipidomic data can be used as a diagnosing tool at the early stages of Alzheimer's disease allowing novel therapeutic targets. In this review, altered lipid metabolites as well as the impact of diet in the progress of Alzheimer's disease (AD) are analyzed.

Entities:  

Keywords:  Alzheimer’s disease; Brain lipidomics; Ceramides; Cholesterol; Essential fatty acids; Lipid metabolites; MCI Chapter 16; Saturated fat; Sphingolipids

Mesh：

Substances：

Year:  2020        PMID： 32468464     DOI： 10.1007/978-3-030-32633-3_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  40 in total

Review 1.  Prostaglandins and other lipid mediators in Alzheimer's disease.

Authors:  Nicolas G Bazan; Vittorio Colangelo; Walter J Lukiw
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

Review 2.  Dietary lipids and their oxidized products in Alzheimer's disease.

Authors:  Laura Corsinovi; Fiorella Biasi; Giuseppe Poli; Gabriella Leonarduzzi; Gianluca Isaia
Journal:  Mol Nutr Food Res       Date:  2011-08-31       Impact factor: 5.914

Review 3.  Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease.

Authors:  Baukje de Roos; Yiannis Mavrommatis; Ingeborg A Brouwer
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

4.  Endolysosome mechanisms associated with Alzheimer's disease-like pathology in rabbits ingesting cholesterol-enriched diet.

Authors:  Xuesong Chen; John F Wagener; Daniel H Morgan; Liang Hui; Othman Ghribi; Jonathan D Geiger
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease.

Authors:  M Combrinck; J Williams; M A De Berardinis; D Warden; M Puopolo; A D Smith; L Minghetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06-08       Impact factor: 10.154

6.  Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease.

Authors:  Frédéric Calon; Giselle P Lim; Takashi Morihara; Fusheng Yang; Oliver Ubeda; Norman Salem; Sally A Frautschy; Greg M Cole
Journal:  Eur J Neurosci       Date:  2005-08       Impact factor: 3.386

Review 7.  Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids.

Authors:  P C Calder
Journal:  Braz J Med Biol Res       Date:  1998-04       Impact factor: 2.590

8.  Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis.

Authors:  Kaarin J Anstey; Darren M Lipnicki; Lee-Fay Low
Journal:  Am J Geriatr Psychiatry       Date:  2008-05       Impact factor: 4.105

Review 9.  The blood-brain barrier in neurodegenerative disease: a rhetorical perspective.

Authors:  Paul M Carvey; Bill Hendey; Angela J Monahan
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

10.  Neuroprotectin D1 upregulates Iduna expression and provides protection in cellular uncompensated oxidative stress and in experimental ischemic stroke.

Authors:  Ludmila Belayev; Pranab K Mukherjee; Veronica Balaszczuk; Jorgelina M Calandria; Andre Obenaus; Larissa Khoutorova; Sung-Ha Hong; Nicolas G Bazan
Journal:  Cell Death Differ       Date:  2017-04-21       Impact factor: 15.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.